AccessibilityHelp
Trinity Biotech Plc logo

Trinity Biotech Plc(NASDAQ) TRIB

Market Cap$4.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-100%
5 Year-98%
1 Year-74%
1 Month+4%
$7.30
-2.81%
-0.21Today
Trinity Biotech Plc last closing stock price
MetricPriceDate
Last closeUSD 7.302026-10-23
Trinity Biotech Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.1%USD 8.032026-10-16
1 month+4.13%USD 7.012026-09-23
3 month-13.57%USD 8.452026-07-24
Year to date-69.24%USD 23.732025-12-31
1 year-74.29%USD 28.392025-10-23
3 year-90.07%USD 73.502023-10-24
5 year-97.68%USD 315.002021-10-22
Since inception-99.68%USD 2,266.921992-10-21

Trinity Biotech Plc Financials at a Glance

Market Cap

$4.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$43.86M

Net Income (TTM)

-$37.43M

EPS (TTM)

-$52.93

P/E Ratio

-0.14

Dividend

$0.00

Beta (Volatility)

0.69 (Low)

Price

$7.30

Volume

14,683

Open

$7.59

Previous Close

$7.30

Daily Range

$7.27 - $7.80

52-Week Range

$5.01 - $52.50

Estimated Earnings Date

Sep 3, 2026

TRIB News

market crash image023 getty 1

Why Trinity Biotech Is Crashing 51% Today

Todd CampbellOct 4, 2016

Ireland Continues Turning the Screws ... on Itself

Matt KoppenhefferNov 4, 2011

Should You Get Out of Meridian Bioscience Before Next Quarter?

Seth JaysonOct 17, 2011

5-Star Stocks on the Upswing

Motley Fool StaffOct 30, 2008

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Trinity Biotech Plc

Trinity Biotech plc is an Irish company specializing in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. Founded in 1992 and headquartered in Bray, the company serves diverse markets across the Americas, Africa, Asia, and Europe.

Products and Services
  • Diagnostic tests for infectious diseases, including Lyme disease and STIs
  • In-vitro diagnostic products for diabetes monitoring, focusing on haemoglobin A1c
  • Specialized instrumentation and reagent products for clinical laboratories
Growth Outlook
  • Expansion into emerging markets is anticipated to drive revenue growth
  • Increased demand for point-of-care diagnostics is expected to enhance market presence
  • Investment in R&D aims to innovate and diversify product offerings
Financial Highlights
  • Recent quarterly revenue of $11.06 million reflects a strategic recovery
  • Trailing twelve months (TTM) gross profit margin stands at 38.48%
  • Cash and cash equivalents increased to $5.14 million in Q4 2025
Trinity Biotech plc operates in the medical diagnostics sector, focusing on innovative solutions for infectious diseases and diabetes management. The company's extensive product range includes diagnostic tests and specialized instruments, catering to both clinical laboratories and point-of-care settings. Recent financial performance indicates a revenue of $11.06 million in the latest quarter, showcasing a strategic recovery from previous periods. The TTM gross profit margin of 38.48% highlights the company's ability to maintain profitability despite challenges. The growth outlook for Trinity Biotech is promising, with plans to expand into emerging markets and capitalize on the increasing demand for point-of-care diagnostics. Investments in research and development are expected to foster innovation and diversify the product portfolio, positioning the company for future success. The recent increase in cash reserves to $5.14 million in Q4 2025 further strengthens the company's financial stability, providing a solid foundation for ongoing operations and growth initiatives.
AI Generated • Oct 18, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

287

CEO

John Gillard

Website

www.trinitybiotech.com

Headquarters

Bray, WW A98 H5C8, IE

TRIB Financials

Key Financial Metrics (TTM)

Gross Margin

38.48%

Operating Margin

-17.97%

Net Income Margin

-78.88%

Return on Equity

48.72%

Return on Capital

-17.30%

Return on Assets

-27.22%

Earnings Yield

-7.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

644.60K

Volume

14.68K

Avg. Volume

22.40K

Financials (TTM)

Gross Profit

$15.53M

Operating Income

-$11.26M

EBITDA

-$8.57M

Operating Cash Flow

-$6.26M

Capital Expenditure

-$88.26K

Free Cash Flow

-$6.34M

Cash & ST Invst.

$5.14M

Total Debt

$137.98M

Trinity Biotech Plc Performance Analysis

Trinity Biotech Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 62,555,247-32.6%
20232023-12-31USD 56,920,020-9.0%
20242024-12-31USD 61,446,2668.0%
20252025-12-31USD 43,920,480-28.5%
Trinity Biotech Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-52.2%
Q22025-06-3044.9%
Q32025-09-3029.8%
Q42025-12-31-22.3%
Trinity Biotech Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -182.45N/A
20232023-12-31USD -94.27-48.3%
20242024-12-31USD -53.01-43.8%
20252025-12-31USD -60.5514.2%
Trinity Biotech Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3159.7%
Q22025-06-3032.8%
Q32025-09-3015.4%
Q42025-12-31-243.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$11.06M

-30.2%

Gross Profit

$3.55M

-27.3%

Gross Margin

32.05%

N/A

Market Cap

$4.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$16.39K

N/A

Employees

287

N/A

Net Income

-$17.46M

-3.0%

EBITDA

-$2.21M

+76.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$5.14M

-0.6%

Total Debt

$137.98M

+36.9%

Accounts Receivable

$10.28M

-29.6%

Inventory

$18.83M

-2.8%

Long Term Debt

$27.17M

-72.4%

Short Term Debt

$110.81M

+4341.4%

Return on Assets

-27.22%

N/A

Return on Invested Capital

18.10%

N/A

Free Cash Flow

-$1.54M

-350.6%

Operating Cash Flow

-$1.55M

-146.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ADVBAdvanced Biomed Inc. Common Stock
$3.17-8.38%
EVGNEvogene Ltd.
$0.36-3.14%
BGLCBioNexus Gene Lab Corp.
$1.19+0.00%
XAIRBeyond Air, Inc.
$2.09-9.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About TRIB

What is the current price of Trinity Biotech Plc?

Trinity Biotech Plc is trading at $7.30 per share.

What is the 52-week range for Trinity Biotech Plc?

Over the past 52 weeks, Trinity Biotech Plc has traded between $5.01 and $52.50.

How much debt does Trinity Biotech Plc have?

As of the most recent reporting period, Trinity Biotech Plc reported total debt of $137.98M.

How much cash does Trinity Biotech Plc have on hand?

Trinity Biotech Plc reported $5.14M in cash and cash equivalents in its most recent financial results.

What is Trinity Biotech Plc’s dividend yield?

Trinity Biotech Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services